Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.

Vicore advances on new chemical entity from VP03 program

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022

Agilent posts Q1 FY2022 revenue at US$ 1.67 billion

Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.

Merck completes acquisition of biopharma CDMO Exelead

Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science

Biosion appoints Joel Edwards as Chief Business Officer

Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.

PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery

He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,

Daewoong Pharmaceutical posts strong financials in 2021

Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.

Prestige BioPharma’s Tuznue receives EU-GMP certification

World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China

Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue